General Information of DME (ID: DMEN068)
DME Name	Plasma esterase (PE), .
Gene Name	PE
Click to Show/Hide the Molecular/Functional Data (Sequence/Structure/Pathway/Function) of This DME

Full List of Drug(s) Metabolized by This DME
Drugs in Phase 2 Clinical Trial			Click to Show/Hide the Full List of Drugs:          1 Drugs
BCP-13498	Drug Info	Phase 2	Anaesthesia	ICD11: 8E22	[1]

Full List of Metabolic Reactions (MR) Catalyzed by This DME
MR ID Reactant Product MR Type Source Drug REF MR007295 BCP-13498 Paracetamol Unclear - Unclear BCP-13498 [1] MR007299 BCP-13498 N, N-diethylglycine Unclear - Unclear BCP-13498 [1] MR001027 Fesoterodine Fesoterodine 5-hydroxymethyl tolterodine Hydrolysis - Hydrolysis Fesoterodine [2], [3], [4] MR007809 Omacetaxine mepesuccinate 4'-DMHHT Hydrolysis - Hydrolysis Omacetaxine mepesuccinate [5] MR003390 Otilonium bromide (OB) DP-1 Hydrolysis - Hydrolysis Otilonium [6] MR003391 Otilonium bromide (OB) DP-2 Hydrolysis - Hydrolysis Otilonium [6] ⏷ Show the Full List of 6 MR(s)

References
1	DrugBank(Pharmacology-Metabolism):BCP-13498
2	Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron J Clin Pharmacol. 2019 Nov;59(11):1505-1518. doi: 10.1002/jcph.1438.
3	Population Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients?with Neurogenic Detrusor Overactivity. Eur J Drug Metab Pharmacokinet. 2023 May;48(3):257-269. doi: 10.1007/s13318-023-00818-8.
4	Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study. J Pediatr Urol. 2023 Apr;19(2):175.e1-175.e10. doi: 10.1016/j.jpurol.2022.11.020.
5	PubChem:Omacetaxine mepesuccinate
6	Determination of the unstable drug otilonium bromide in human plasma by LC-ESI-MS and its application to a pharmacokinetic study J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Oct 15;878(28):2896-900. doi: 10.1016/j.jchromb.2010.08.003.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.